0000899243-23-014998.txt : 20230608
0000899243-23-014998.hdr.sgml : 20230608
20230608211528
ACCESSION NUMBER: 0000899243-23-014998
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230403
FILED AS OF DATE: 20230608
DATE AS OF CHANGE: 20230608
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: SMITH IAN F
CENTRAL INDEX KEY: 0001197032
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38360
FILM NUMBER: 231003649
MAIL ADDRESS:
STREET 1: C/O ACORDA THERAPEUTICS, INC.
STREET 2: 420 SAW MILL RIVER ROAD
CITY: ARDSLEY
STATE: NY
ZIP: 10502
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Solid Biosciences Inc.
CENTRAL INDEX KEY: 0001707502
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 900943402
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 500 RUTHERFORD AVENUE
STREET 2: 3RD FLOOR
CITY: CHARLESTOWN
STATE: MA
ZIP: 02129
BUSINESS PHONE: 617-337-4680
MAIL ADDRESS:
STREET 1: 500 RUTHERFORD AVENUE
STREET 2: 3RD FLOOR
CITY: CHARLESTOWN
STATE: MA
ZIP: 02129
FORMER COMPANY:
FORMER CONFORMED NAME: Solid Biosciences, LLC
DATE OF NAME CHANGE: 20170524
4
1
doc4.xml
FORM 4 SUBMISSION
X0407
4
2023-04-03
0
0001707502
Solid Biosciences Inc.
SLDB
0001197032
SMITH IAN F
C/O SOLID BIOSCIENCES INC.
500 RUTHERFORD AVENUE
CHARLESTOWN
MA
02129
1
0
0
0
0
Common Stock
2023-04-03
4
M
0
15569
A
53239
D
Restricted Stock Units
2023-04-03
4
M
0
15569
0.00
D
Common Stock
15569
46709
D
Director Stock Option (Right to Buy)
6.37
2023-06-06
4
A
0
9650
0.00
A
2033-06-06
Common Stock
9650
9650
D
Restricted stock units convert into common stock on a one-for-one basis.
The restricted stock units were granted on January 3, 2023 (the "Grant Date") and vest in equal quarterly installments beginning three months from the Grant Date, with the final installment vesting the date that is 12 months from the Grant Date; provided that in the event of the early termination of the First Amendment to Executive Chair Agreement between the Issuer and the reporting person (the "Smith Agreement") prior to the expiration of the Term (as defined in the Smith Agreement) and/or a change in control of the Issuer, the restricted stock units shall accelerate in full.
This option was granted on June 6, 2023 and vests in full on the earlier to occur of the one-year anniversary of the grant date and immediately prior to the Issuer's next annual meeting of stockholders occurring after the grant date, and will vest automatically as to 100% of the unvested portion of such option upon specified change in control events.
/s/ David Tyronne Howton as attorney-in-fact for Ian F. Smith
2023-06-08